Alignment Healthcare (ALHC) Beats on Earnings, But Misses Revenue; Stock Slides After-Hours
Alignment Healthcare (NASDAQ:ALHC) reported first-quarter results for 2026 that showcased a significant improvement in profitability, though the market’s initial reaction has been negative. The stock is trading roughly 8% lower in after-hours trading, a move that appears to be driven by a revenue figure that came in just shy of analyst expectations.
Revenue and EPS vs. Estimates
The headline numbers present a mixed picture relative to Wall Street estimates. While the company delivered strong year-over-year growth, it fell slightly short on the top line.
- Revenue: The company reported total revenue of $1.235 billion for the quarter. This represents a substantial 33.3% increase compared to the same period last year but fell short of the consensus analyst estimate of approximately $1.242 billion.
- Earnings Per Share (EPS): On a non-GAAP basis, Alignment Healthcare posted earnings per share of $0.05. This was a significant beat over the analyst consensus estimate of $0.0074, marking a clear positive surprise on the bottom line.
The revenue miss, even by a narrow margin, appears to be the primary catalyst for the negative price action, overshadowing the strong earnings beat.
First Quarter Key Highlights
Beyond the headline figures, the Q1 release highlighted several operational strengths and a strategic shift toward profitable growth.
- Membership Growth: The company grew its Medicare Advantage membership by 30.9% year-over-year, reaching approximately 284,800 members at the end of the quarter.
- Margin Expansion: Adjusted gross profit rose 36.1% year-over-year to $145.9 million. The medical benefits ratio (MBR) improved by 25 basis points to 88.2%, indicating better cost management.
- Profitability Milestone: The company reported net income of $11.4 million, a dramatic turnaround from a net loss of $9.4 million in the first quarter of 2025. Adjusted EBITDA surged 87.6% to $37.9 million, translating to a 3.1% margin.
CEO John Kao attributed the performance to disciplined growth across sales, clinical operations, and cost management, stating the company is "investing in our people, processes and technologies" to scale the business and achieve its earnings potential.
Full-Year Outlook vs. Analyst Estimates
Management’s updated outlook for the full year 2026 provides context for the company’s trajectory and was a key element of the release.
- Raised Guidance: Alignment Healthcare raised the midpoint of its guidance for membership, revenue, adjusted gross profit, and adjusted EBITDA.
- Revenue Outlook: The company guided for full-year 2026 revenue in a range of $5.160 billion to $5.205 billion. The midpoint of this range is approximately $5.183 billion, which is below the current analyst consensus estimate of $5.277 billion.
- Adjusted EBITDA Outlook: The company expects full-year adjusted EBITDA between $138 million and $163 million.
The fact that the company's own raised revenue guidance still lands below what analysts were expecting likely contributed to the negative market sentiment, reinforcing the idea that the revenue miss was not just a one-quarter phenomenon but could signal a more tempered growth trajectory than the market had anticipated.
Market Reaction Summary
The stock’s after-market decline of nearly 8% suggests that investors are focusing heavily on the revenue shortfall and the conservative full-year guidance compared to consensus. While the dramatic improvement in profitability and the earnings beat are clear positives, the market is clearly pricing in disappointment regarding the top-line growth outlook.
Looking Ahead
For a detailed view of past earnings performance and to track future projections against these new estimates, you can view the complete earnings history and analyst ratings for Alignment Healthcare at its earnings page and forecast page.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. You should consult with a qualified financial professional before making any investment decisions.